Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis

NCT03325621 is registered in ClinicalTrials.gov with Pieris Pharmaceuticals GmbH as lead sponsor.

NCT NCT03325621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03325621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis
Lead sponsor
Pieris Pharmaceuticals GmbH
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2017
Completion date
June 30, 2019
Enrollment
11 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic kidney disease